



(51) International Patent Classification:

A61K 9/22 (2006.01) A61K 31/496 (2006.01)
A61K 9/52 (2006.01) A61K 31/505 (2006.01)
A61K 45/06 (2006.01) A61P 25/14 (2006.01)
A61K 31/422 (2006.01) A61P 25/16 (2006.01)
A61K 31/454 (2006.01) A61K 9/28 (2006.01)
A61K 31/4545 (2006.01)

(21) International Application Number:

PCT/DK2013/050111

(22) International Filing Date:

18 April 2013 (18.04.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2012 70196 18 April 2012 (18.04.2012) DK
PCT/DK2012/050190 1 June 2012 (01.06.2012) DK
PA 2012 70755 4 December 2012 (04.12.2012) DK

(71) Applicant: **CONCIT PHARMA APS** [DK/DK]; c/o John Bondo Hansen, Langåsen 3, DK-4450 Jyderup (DK).

(72) Inventors: **HANSEN, John Bondo**; Langåsen 3, DK-4450 Jyderup (DK). **THOMSEN, Mikael S.**; Hvidovre Allé 18, DK-2650 Hvidovre (DK). **MIKKELSEN, Jens D.**; Borgevej 9, DK-2800 Lyngby (DK). **NIELSEN, Peter Gudmund**; Klosterbakken 22, DK-3500 Værløse (DK).

KREILGAARD, Mads; Brudedalen 32, DK-3520 Farum (DK).

(74) Agent: **HØIBERG A/S**; St. Kongensgade 59 A, DK-1264 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ORALLY AVAILABLE PHARMACEUTICAL FORMULATION SUITABLE FOR IMPROVED MANAGEMENT OF MOVEMENT DISORDERS




Figure 9

(57) Abstract: The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT_{1B}, 5-HT_{1D} and 5-HT_{1F} receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT_{1A}-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*